多原发黑色素瘤患者的癌症风险与生存:家族史及胚系CDKN2A突变状态的影响
研究基于瑞典国家登记数据,分析多原发黑色素瘤(MPM)患者的家族史和胚系CDKN2A突变状态对后续黑色素瘤、其他癌症风险及生存的影响。结果显示,携带CDKN2A突变的家族性MPM患者第二次黑色素瘤诊断年龄最轻(中位42岁),后续发生>2个黑色素瘤的相对风险最高(RR 238.4),且非皮肤癌风险增加、生存更差。
要点
- CDKN2A突变家族性MPM患者第二次黑色素瘤诊断中位年龄42岁,后续>2个黑色素瘤风险显著增高。
- CDKN2A突变MPM患者及其一级亲属非皮肤癌风险增加。
- CDKN2A突变MPM患者生存较家族性和散发性野生型MPM患者更差。
核心结论
- CDKN2A突变状态和黑色素瘤家族史显著影响多原发黑色素瘤患者的结局。
研究设计与样本
- 基于瑞典全国医疗和人口登记数据,获取MPM患者、其一级亲属及匹配对照的癌症诊断和死亡综合数据。
主要发现
- 家族性MPM伴胚系CDKN2A突变者第二次黑色素瘤诊断中位年龄42岁,在MPM队列中发生>2个黑色素瘤的相对风险最高(RR 238.4,95% CI 74.8-759.9)。
- CDKN2A突变MPM患者及其一级亲属是仅有的非皮肤癌风险较对照增加的队列(RR 3.6,95% CI 1.9-147.1;RR 3.2,95% CI 1.9-5.6)。
- CDKN2A突变MPM患者生存较家族性(HR 3.0,95% CI 1.3-8.1)和散发性野生型MPM(HR 2.63,95% CI 1.3-5.4)更差。
临床怎么用
- 对多原发黑色素瘤患者应评估黑色素瘤家族史和CDKN2A突变状态,以识别高危亚组并加强后续黑色素瘤及其他癌症监测。
局限性
- 研究按MPM患者亚组分析结局,影响了研究组的样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Worse outcomes have been noted in patients with multiple primary melanomas (MPMs) than in patients with single primary melanomas. OBJECTIVE: We investigated how family history of melanoma and germline CDKN2A mutation status of MPM patients affects risks of developing subsequent melanomas and other cancers and survival outcomes. METHODS: Comprehensive data on cancer diagnoses and deaths of MPM patients, their first-degree relatives, and matched controls were obtained through Swedish national health care and population registries. RESULTS: Familial MPM cases with germline CDKN2A mutations were youngest at the diagnosis of their second melanoma (median age 42 years) and had among the MPM cohorts the highest relative risks (RR) compared to controls of developing >2 melanomas (RR 238.4, 95% CI 74.8-759.9). CDKN2A mutated MPM cases and their first-degree relatives were the only cohorts with increased risks of nonskin cancers compared to controls (RR 3.6, 95% CI 1.9-147.1 and RR 3.2, 95% CI 1.9-5.6, respectively). In addition, CDKN2A mutated MPM cases had worse survival compared with both cases with familial (HR 3.0, 95% CI 1.3-8.1) and sporadic wild-type MPM (HR 2.63, 95% CI 1.3-5.4). LIMITATIONS: Our study examined outcomes in subgroups of MPM patients, which affected the sample size of the study groups. CONCLUSION: This study demonstrates that CDKN2A mutation status and family history of melanoma significantly affects outcomes of MPM patients.
引用
- Helgadottir H, Tuominen R, Olsson H, et al. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. J Am Acad Dermatol. 2017. PMID: 28818438. doi:10.1016/j.jaad.2017.05.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。